Questions and answers
To support you in preparing your application for the EUP OHAMR Joint transnational call 2026, we have compiled answers to the most frequently asked questions from the Webinar for applicants held on 26 November 2025.
General questions about the call and the partnership
Is the call text available as a pdf?
All information is available on the call web page (with sub pages). You can click on the print button on the top of each page to save and/or print as pdf.
How many funding calls will be launched during the duration of the partnership, and what will be the topics and timing? Is this information already available somewhere?
The partnership will launch 6 calls for projects (one call every year) and 3 calls for capacity strengthening and strategic alignment (one call every two years). The calls for projects will be launched every year around the same time (November). The topics of the calls have not been decided yet. Please see our Strategic Research and Innovation Agenda, SRIA, to have a better idea of the topics addressed by the EUP OHAMR Partnership.
General eligibility
Are diagnostics in the scope of the call?
The 2026 call is focused on treatments and adherence to treatment protocols.
What is the expected duration of the projects?
The initial maximum grant duration is 3 years.
How many partners can be included in a consortium?
The consortium can include a maximum of 6 project partners, including non-funded partners.
The maximum number of partners can be increased to 7 if the consortium includes:
- at least one partner from an under-represented country (For the purpose of this call, the under-represented countries are: Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Moldova, Poland, and Slovakia) or
- at least one partner where the Principal Investigator meets the definition of an Early-Career Researcher or
- a start-up, SME, or an Industry.
What is the definition of an Early Career Researcher?
For the purpose of this call, an Early-Career Researcher (ECR) is a PhD holder, up to 8 years after the year of PhD award, holding a position at a recognised institution. The reference point is the closure of this call, i.e 2 February 2026, meaning that the applicants should have obtained their PhD not after the 2. February 2018 to be qualified as an ECR.
The 8-year period may be extended to allow for career breaks including documented parental leave, positions of trust in trade union organisations and student organisations, mandatory military or civil service, illness (own illness or care for close family members), medical internships or medical fellowship (applies to clinically active professionals). The last two categories may involve periods of up to 24 months each.
Please note that the EUP OHAMR definition of an ECR may differ from the national/regional definition.
Can I start with four partners in the pre-proposal and add more partners in the full proposal?
The composition of the consortium cannot be modified between the pre- and full proposal stages, except for widening and in case of unforeseen event (please refer to the “Eligibility” section of the call web page).
What happens if I have a project that spans on several Call Topics?
You will need to choose the topic that best aligns with your proposal.
Is there a template available for writing the pre-proposal and the full proposal?
The link to download the pre-proposal template can be found on the call web page in the section “General conditions for application”. The full proposal template will be sent to the project coordinators invited to the next evaluation stage.
Non-participating countries
Can I participate in a consortium and get funded if I am located in a non-participating country (for example Australia, Georgia, India, Korea, Romania, USA, etc.)?
Yes, you can participate but you cannot request funding through this call. You can join a consortium as a non-funded partner only (in-kind contribution).
Low- and Middle-income Countries (LMICs)
Can institutions from Low- and Middle-income Countries (LMICs) be partners and receive funding?
Research institutions from Moldova, South Africa and Turkey, are able to receive funding in the framework of this call thanks to the participation of their funding organisations.
Partners from LMICs that are not listed as participating countries may still join the Call; however, they will not be eligible to request funding. They must participate using their own independent resources (as non-funded partners) and cannot serve as project coordinators.
Some individual funders might allow funding for LMICs. Is it possible to include an LMIC partner through that route?
Most of the funding organisations participating in the call can only fund their national applicants. Please contact your national funding organisation to check if specific routes for LMIC funding are available.
National eligibility
For all questions regarding national eligibility, such as the examples below, please contact your national/regional funding organisation.
What is the maximum amount of funding I can request?
Is my institution eligible for funding in my country?
Can an industry partner/SME be funded by its national funding organisation?
What are the eligibility criteria for PIs?
Are Human Health and/or Animal Health and/or Plant Health and/or Environment eligible for funding in my country?
Are clinical trials eligible for funding in my country?
Can I coordinate a consortium and also participate in other consortia?
For this call, you may only coordinate one proposal but can participate in several proposals. However, specific rules may apply depending on your funding organisation. Please contact your national funding organisation for the relevant national rules and requirements
Should each project partner follow their own country’s funding regulations, or only those of the project coordinator?
Each partner will receive funding from its own funding organisation and must therefore comply with the regulations set by that organisation.
Partner search tool
We currently have funding and could participate with an in-kind contribution. How can we find partners?
You can use the Partner search tool to find new partners.
How can I register in the Partner search tool as a partner seeking to join a project?
If you are an individual researcher or a representative of a research team searching for a project to join, select: Partner looking for project.
How can I register in the Partner search tool as a partner aiming to build a consortium?
If you want to build a consortium around an existing project, select: Project looking for partner.
Evaluation
Is my proposal aligned with the scope of the selected topic?
Only the evaluation committee can determine whether proposals align with the scope of the relevant topic. This assessment is based on the evaluation criteria outlined in the presentation from the webinar and available in the page Evaluation process and criteria.
Topic 1: Combination
Is combination therapy mandatory, or can a single innovative treatment be funded?
Combination therapy is mandatory. Single-agent approaches are not eligible.
Is developing a new antimicrobial allowed under Topic 1?
Yes, but only if the new antimicrobial is used in combination with another antimicrobial or an adjuvant.
Can new antimicrobials or innovative agents (e.g., new drugs, coatings, phages) be included in a combination?
Yes. New or innovative antimicrobials are eligible if they are part of a combination.
Are combinations using only existing antimicrobials eligible?
Yes. Combinations of existing antimicrobials fall within the scope.
Are combinations of an antimicrobial with a non-antimicrobial adjuvant eligible?
Yes. Antimicrobial and non-antimicrobial adjuvant combinations are eligible.
Can a project focus solely on optimising existing antimicrobial treatments?
Yes, provided the optimisation involves a combination strategy.
Can the project include a work package analysing resistance development?
Yes. Resistance studies are acceptable within a combination-based project.
Topic 1: Pathogens
Is a One Health approach required, or may proposals focus solely on human health?
It’s not necessary to include two One-Health settings in proposals addressing the Topic 1. Proposals focused exclusively on human health are eligible under Topic 1. The relevance of the proposal to the selected One Health setting(s) must be clearly specified.
Please check your national rules and requirements to ensure that the One-Health setting considered is eligible for your national/regional funding organisation.
Can a Topic 1 proposal focus on two co-existing WHO priority pathogens?
Yes.
Does Topic 1 only cover pathogens listed in the WHO priority catalogue, or can other pathogens (e.g., animal pathogens) be targeted?
For proposals with a human health focus, targeted pathogens must be from the WHO priority bacterial or fungal lists. In other One Health contexts, other pathogens may be considered. In this case, the choice of the targeted pathogens should be well justified.
Can a proposal focus exclusively on animal health, or on both human and animal health? If so, must WHO-listed pathogens be included?
Yes, proposals may focus solely on animal health or address both human and animal health. However, if human health is included, at least one targeted pathogen must be from the WHO priority list.
Can a proposal address one WHO priority pathogen together with additional non-priority pathogens?
Yes.
Is it mandatory to target pathogens listed in the WHO priority list for human health proposals?
Yes. For proposals focusing on human health, the pathogens addressed must be included in the WHO bacterial or fungal priority list.
Are parasitic diseases such as malaria eligible for Topic 1?
No. Topic 1 is limited to antimicrobial resistance in bacteria and fungi, not parasites, nor viruses.
Topic 2
Who is considered an “end-user” in Topic 2?
End-users are defined as patients, farmers, and citizens — the individuals who must follow treatment protocols in practice.
What is meant by “protocols” in Topic 2? Does this refer to clinician prescribing rules, or to instructions given to patients?
“Protocols” refer to the instructions and guidelines that end-users must follow, such as dosage, duration, timing, and proper use of antimicrobials. It does not refer to prescribing regulations or clinician decision rules.
Does Topic 2 include improving antibiotic prescribing, or does it focus only on patient adherence? Are strategies for more targeted prescribing out of scope?
Topic 2 focuses exclusively on end-users’ adherence to treatment protocols (patients, farmers, citizens). Improving or optimising prescription practices or targeted prescribing by clinicians is out of scope.
Does Topic 2 focus only on adherence in human health?
No. Adherence by patients, farmers, and citizens can relate to human, animal, or plant—provided the focus remains on end-user compliance.
Can diagnostic tools/methods be considered “innovative tools” under Topic 2? If yes, what characteristics should they have?
If you would like to include diagnostic tools/methods in a proposal addressing Topic 2, you need to show how they will directly contribute to the adherence of the end-users. Tools aimed solely at improving prescribing (e.g., stewardship diagnostics) are out of scope.
Are implementation-science approaches for developing tools to improve adherence relevant to Topic 2? Can physicians still be project partners?
Yes. Implementation-science approaches to improve end-user adherence are fully relevant.
Physicians may participate as partners or contributors, but they are not considered end-users and should not be the primary focus of adherence-related interventions.
Can projects in Topic 2 include citizen-science components?
Yes. Citizen-science approaches are acceptable when they meaningfully engage end-users (patients, farmers, citizens) and support improved adherence to treatment protocols.
Topic 3
Does Topic 3 require addressing all the objectives listed (mechanisms of action, formulations, PK/PD, routes of administration, etc.)? Or can proposals focus on selected elements, considering limited budgets?
Topic 3 describes the full scope of aspects that may be addressed, but proposals are not required to cover every element. They must clearly fit within the overall aim of assessing the impact of veterinary/agricultural antimicrobial use on AMR transmission and/or improving treatments to reduce this risk. The evaluation committee will ultimately determine whether the proposed focus is adequate.
Does Topic 3 only concern antimicrobials already in use in veterinary and agricultural settings? Are “new” therapies excluded?
Yes. Topic 3 explicitly concerns antibacterial and antifungal drugs already authorized for veterinary or agricultural use. “New” therapies are not within scope unless they are already in use in these sectors.
What is meant by “including pharmacokinetics and pharmacodynamics” in the context of improving formulations, dosages and routes of administration?
Pharmacokinetics (PK) and pharmacodynamics (PD) refer to the absorption, distribution, metabolism and excretion of antimicrobials, and their dose–response relationships. In Topic 3, PK/PD studies may be included to optimise existing veterinary/agricultural antimicrobial uses—e.g., refining treatment regimens to reduce AMR emergence, cross-resistance, or transmission to humans and the environment.